Vicente Merino Bohorquez

Profesor Asociado CIS
vmerino1@us.es
Área de conocimiento: Farmacología
Departamento: Farmacología
Grupo: Desarrollo galénico de medicamentos y productos cosméticos (CTS-1015)
Tipo Año Título Fuente
Artículo2021 Activity of fosfomycin and amikacin against fosfomycin-heteroresistant Escherichia coli strains in a hollow-fiber infection model ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Artículo2021 Pharmacogenetics of trough serum anti-TNF levels in paediatric inflammatory bowel disease British Journal of Clinical Pharmacology
Artículo2021 Population Pharmacokinetics of Piperacillin in Non-Critically Ill Patients with Bacteremia Caused by Enterobacteriaceae. Antibiotics
Artículo2021 Role of inorganic phosphate concentrations in in vitro activity of fosfomycin CLINICAL MICROBIOLOGY AND INFECTION
Artículo2021 Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): protocol for a randomised, pragmatic trial BMJ OPEN
Artículo2021 Whole transcription profile of responders to anti-TNF drugs in pediatric inflammatory bowel disease PHARMACEUTICS
Artículo2020 Buenas prácticas de trabajo en equipos multidisciplinares para la atención al paciente con asma grave no controlada (Proyecto TEAM) FARMACIA HOSPITALARIA
Artículo2020 Cut-off ranges of infliximab serum levels in Crohn's disease in the clinical practice Revista Española de Enfermedades Digestivas
Artículo2020 Formulation, long-Term physicochemical and microbiological stability of 15% topical resorcinol for hidradenitis suppurativa EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE
Artículo2020 Gene signatures of early response to anti-TNF drugs in pediatric inflammatory bowel disease INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Artículo2020 Genetic predictors of long-term response to antitumor necrosis factor agents in pediatric inflammatory bowel disease Journal of Pediatric Gastroenterology and Nutrition
Artículo2019 A case of pan-resistant Burkholderia cepacia complex bacteremic pneumonia, after lung transplantation treated with a targeted combination therapy TRANSPLANT INFECTIOUS DISEASE
Artículo2019 Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data Therapeutic Advances in Gastroenterology
Artículo2019 Physicochemical and microbiological stability of two news oral liquid formulations of clonidine hydrochloride for pediatric patients PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY
Artículo2019 Preparation and Characterization of New Liposomes. Bactericidal Activity of Cefepime Encapsulated into Cationic Liposomes PHARMACEUTICS
Resumen congreso2018 Comparison of the efficacy of infliximab biosimilar (Remsima (R)) vs. infliximab original (Remicade (R)) in patients with inflammatory bowel disease JOURNAL OF CROHNS & COLITIS
Artículo2018 Estudio piloto sobre la utilidad de la monitorización de niveles y anticuerpos anti-infliximab en pacientes con Enfermedad Inflamatoria Intestinal en práctica clínica. Estudio "Inflixilevel". Revista Andaluza de Patología Digestiva
Artículo2018 Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: Multicentric study FARMACIA HOSPITALARIA
Artículo2018 Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease WORLD JOURNAL OF GASTROENTEROLOGY
Artículo2018 Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli CLINICAL MICROBIOLOGY AND INFECTION
Resumen congreso2018 Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: Multicentre study at 12 months results JOURNAL OF CROHNS & COLITIS
Artículo2018 Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months Revista Española de Enfermedades Digestivas
Artículo2017 Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months DIGESTIVE DISEASES AND SCIENCES
Corrección2017 Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months DIGESTIVE DISEASES AND SCIENCES
Artículo2017 Estudio de estabilidad fisico-química y microbiológica de dos nuevas formulaciones de clorhidrato de clonidina para uso pediátrico Acofar 557: revista de la distribución farmacéutica cooperativista
Artículo2017 Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
Resumen congreso2016 Safety and efficacy of infliximab biosimilar (Remsima (c)) in Crohn's disease patients in clinical practice: results after 6 months of treatment JOURNAL OF CROHNS & COLITIS
Resumen congreso2016 Safety and efficacy of infliximab biosimilar (Remsima (c)) in ulcerative colitis disease patients in clinical practice: results after 6-months treatment JOURNAL OF CROHNS & COLITIS
Artículo2015 Fosfomycin versu meropenem in bacteraemic urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial BMJ OPEN
Ponencia2015 Fosfomycin Versus Meropenem In Bacteremic Urinary Tract Infections Caused By Extended-Spectrum Betalactamase Producing Escherichia Coli (Esbl-Ec): Forest Study CLINICAL THERAPEUTICS
Artículo2015 Physicochemical stability of a new topical timolol 0.5% gel formulation for the treatment of infant hemangioma PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY
Revisión2013 Intravitreal bevacizumab syringes: Working protocol ATENCION FARMACEUTICA
Este investigador no ha dirigido/tutorizado tesis

Proyectos de Investigación

Fecha de inicio Fecha de fin Rol Denominación Agencia financiadora
05/10/2021 31/12/2022 Investigador/a Caracterización y optimización de la actividad de temocilina frente a enterobacterias resistentes a cefalosporinas de tercera generación (P20_00985) Consejería de Economía, Conocimiento, Empresas y Universidad (Autonómico)